Research ArticleFeatured Basic Science Article
Open Access
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo and Zhibo Liu
Journal of Nuclear Medicine June 2022, 63 (6) 952-958; DOI: https://doi.org/10.2967/jnumed.121.262533
Mengxin Xu
1Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, China;
Pu Zhang
1Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, China;
Jie Ding
2Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; and
Junyi Chen
1Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, China;
Li Huo
2Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; and
Zhibo Liu
1Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, China;
3Peking University–Tsinghua University Center for Life Sciences, Beijing, China
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 63, Issue 6
June 1, 2022
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo, Zhibo Liu
Journal of Nuclear Medicine Jun 2022, 63 (6) 952-958; DOI: 10.2967/jnumed.121.262533